π΅οΈ Entera BIO Ltd. ($ENTX)
SEC insider & ownership activity, last 12 months Β· CIK 1638097 Β· every row links its SEC filing
Over the last 12 months insiders bought $141K with no open-market selling against it. Geno J. Germano bought $56K in discretionary trades (FebβMar). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
5 buyers, $141K (8 lots) Β· 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Geno J. Germano | 2 | $56K | 0 | β | Mar 9, 2026 |
| Ellis Sean | 2 | $35K | 0 | β | Mar 5, 2026 |
| Toledano Miranda Jayne | 1 | $20K | 0 | β | Dec 29, 2025 |
| Steven D. Rubin | 2 | $19K | 0 | β | Feb 12, 2026 |
| Taitel Haya | 1 | $11K | 0 | β | Feb 10, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| OPKO Health, Inc. | 8.1% | 13G | Apr 2, 2025 | filing β |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material agreement (1.01) | Jul 26, 2026 | filing β |
| Unregistered equity sale (3.02) | Jul 26, 2026 | filing β |
| Officer/director changes (5.02) | Jul 26, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Jul 26, 2026 | filing β |
| Officer/director changes (5.02) | Jul 14, 2026 | filing β |
| Charter/bylaw changes (5.03) | Jul 14, 2026 | filing β |
| Shareholder vote (5.07) | Jul 14, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Jul 14, 2026 | filing β |
| Earnings (2.02) | May 8, 2026 | filing β |
| Reg FD disclosure (7.01) | May 8, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | May 8, 2026 | filing β |
| Material agreement (1.01) | Apr 1, 2026 | filing β |
| Unregistered equity sale (3.02) | Apr 1, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Apr 1, 2026 | filing β |
| Earnings (2.02) | Mar 27, 2026 | filing β |
| Reg FD disclosure (7.01) | Mar 27, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Mar 27, 2026 | filing β |
| Reg FD disclosure (7.01) | Mar 4, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Mar 4, 2026 | filing β |
| Officer/director changes (5.02) | Feb 4, 2026 | filing β |
| Reg FD disclosure (7.01) | Feb 4, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Feb 4, 2026 | filing β |
| Material agreement (1.01) | Jan 29, 2026 | filing β |
| Officer/director changes (5.02) | Jan 29, 2026 | filing β |
| Reg FD disclosure (7.01) | Jan 29, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Jan 29, 2026 | filing β |
| Earnings (2.02) | Nov 14, 2025 | filing β |
| Reg FD disclosure (7.01) | Nov 14, 2025 | filing β |
| Financial Statements and Exhibits (9.01) | Nov 14, 2025 | filing β |
| Earnings (2.02) | Aug 8, 2025 | filing β |